EVEREST II was a multicenter randomized controlled study that compared the MitraClip system (Abbott Structural, Santa Clara, CA) with conventional surgery in 279 patients moderate-to-severe or severe symptomatic chronic mitral regurgitation. 178 patients received the MitraClip and 80 patients underwent surgery. At 5-year follow-up, freedom from death, surgery or 3+ or 4+ mitral regurgitation in the as-treated population was 44% in the MitraClip arm versus 64% in the conventional mitral valve surgery arm. Five-year morality was 21% in the MitraClip arm versus 27% in the surgical arm. The U.S. Food and Drug Administration, in 2013, approved the MitraClip system to reduce mitral regurgitation in patients with moderate-to-severe or severe degenerative mitral regurgitation at prohibitive risk for mitral valve surgery.

All Editors: Kalkidan Bishu, MD, MS, FSCAI

Other Specialist Resources for Structural Heart Disease

Including recently published studies, coverage of late-breaking science, updates from clinical trials and registries, and complex case presentations. 

Clinical Interest Article

PARTNER 3—Coverage of TCT 2021

Two-year economic outcomes from a randomized trial of TAVR vs. SAVR in patients at low surgical risk.
Clinical Interest Article

TRISCEND—Coverage of TCT 2021

Six-month outcomes of transfemoral tricuspid valve replacement in patients with tricuspid regurgitation